Following dreaMS Study VS1, we are currently conducting dreaMS Clinnova study. This study is an international research project designed to validate the digital biomarkers generated through the dreaMS software. It builds on the previous DreaMS VS1 study, which included 300-400 patients with multiple sclerosis and assessed the clinical validity of candidate digital biomarkers (cDB) related to movement, balance, dexterity, vision, and cognition. Clinnova involves a larger international population, systematically replicating the results of VS1 while extending the evaluation to additional patient-relevant outcomes such as hospitalizations and quality of life. Sub-studies and deep phenotyping are included for more detailed analysis, and patients are actively involved in the study’s design and dissemination activities.
